Expressional correlation of Toll-like Receptor 9 (TLR9) with angiogenic factors and anti-apoptotic markers in cervical cancer cells

Ahmed Alharbi; Waleed Mansi Alshammari; Turki A K Alreshidi; Ahmed Alharbi; Waleed Mansi Alshammari; Turki A K Alreshidi

doi:10.3934/medsci.2021002

AIMS Medical Science

2021, Volume 8, Issue 1: 11-22. doi: 10.3934/medsci.2021002

Previous Article Next Article

Research article

Expressional correlation of Toll-like Receptor 9 (TLR9) with angiogenic factors and anti-apoptotic markers in cervical cancer cells

1.
Department of Clinical Laboratory Sciences, College of Applied Medical sciences, University of Hail, Hail, KSA
2.
King Khaled Hospital, Hail, KSA

Received: 12 September 2020 Accepted: 14 December 2020 Published: 11 January 2021

Cervical cancer is one of the most frequently occurring oncological malignancies which in turn is attributed with the chronic persistence of human papillomavirus (HPV). Recent explorations into cancer immunobiology have elucidated that innate immune response are important for proliferation of cancerous cells. Toll-like receptors (TLRs), belonging to the pattern recognition receptors (PRRs) family of innate immune receptors have been reported for their expression in various cancers, where they aid cancer cell proliferation along with tumor development. The present study focuses on investigating TLR9 mRNA within HPV18⁺ HeLa (cervical cancer cells) and its correlation with angiogenic factors and anti-apoptotic markers. The expression of TLR9 mRNA was substantially higher in HeLa cancer cells in comparison with normal kidney cells. MTT assay demonstrated that treatment with CpG ODN significantly increased the proliferation in dose-dependent manner. Augmented levels of cell percentage within G2/M phase was also recorded post CpG ODN treatment within HeLa cells. qRT-PCR analysis also elucidated elevated levels of Bcl-2, Bcl-X_L, COX-2, VEGF, and TLR9 within HeLa cells. Thus, to conclude, our study established that HeLa cells have increased TLR9 mRNA expression concomitant with elevated COX-2, Bcl-2, Bcl-X_L and VEGF. These results indicate toward potential applicability of targeting TLR9 as a therapeutical intervention for the treatment and management of this pernicious malignancy.
- Toll-like receptors,
- apoptosis,
- cervical cancer,
- human papillinoma virus
Citation: Ahmed Alharbi, Waleed Mansi Alshammari, Turki A K Alreshidi. Expressional correlation of Toll-like Receptor 9 (TLR9) with angiogenic factors and anti-apoptotic markers in cervical cancer cells[J]. AIMS Medical Science, 2021, 8(1): 11-22. doi: 10.3934/medsci.2021002

Related Papers:

Abstract

Cervical cancer is one of the most frequently occurring oncological malignancies which in turn is attributed with the chronic persistence of human papillomavirus (HPV). Recent explorations into cancer immunobiology have elucidated that innate immune response are important for proliferation of cancerous cells. Toll-like receptors (TLRs), belonging to the pattern recognition receptors (PRRs) family of innate immune receptors have been reported for their expression in various cancers, where they aid cancer cell proliferation along with tumor development. The present study focuses on investigating TLR9 mRNA within HPV18⁺ HeLa (cervical cancer cells) and its correlation with angiogenic factors and anti-apoptotic markers. The expression of TLR9 mRNA was substantially higher in HeLa cancer cells in comparison with normal kidney cells. MTT assay demonstrated that treatment with CpG ODN significantly increased the proliferation in dose-dependent manner. Augmented levels of cell percentage within G2/M phase was also recorded post CpG ODN treatment within HeLa cells. qRT-PCR analysis also elucidated elevated levels of Bcl-2, Bcl-X_L, COX-2, VEGF, and TLR9 within HeLa cells. Thus, to conclude, our study established that HeLa cells have increased TLR9 mRNA expression concomitant with elevated COX-2, Bcl-2, Bcl-X_L and VEGF. These results indicate toward potential applicability of targeting TLR9 as a therapeutical intervention for the treatment and management of this pernicious malignancy.

Conflicts of interest

All authors declare that there is no conflict of interest.

References

[1]	Tripathi R, Rath G, Jawanjal P, et al. (2019) ≤ Cyclin D1 protein affecting global women's health by regulating HPV mediated adenocarcinoma of the uterine cervix. Sci Rep 9: 5019. doi: 10.1038/s41598-019-41394-9
[2]	Saeed M, Alshammari FD, Alam MJ, et al. (2018) A synopsis on the role of human papilloma virus ınfection in cervical cancer. Curr Drug Metab 19: 798-805. doi: 10.2174/1389200219666180302160317
[3]	Morale MG, da Silva Abjaude W, Silva AM, et al. (2018) HPV-transformed cells exhibit altered HMGB1-TLR4/MyD88-SARM1 signaling axis. Sci Rep 8: 3476. doi: 10.1038/s41598-018-21416-8
[4]	Walboomers JM, Jacobs MV, Manos MM, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
[5]	Saeed M, Faisal SM, Akhtar F, et al. (2020) Human papillomavirus ınduced cervical and oropharyngeal cancers: from mechanisms to potential ımmuno-therapeutic strategies. Curr Drug Metab 21: 167-177. doi: 10.2174/1389200221666200421121228
[6]	Bray F, Ferlay J, Soerjomataram I, et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424. doi: 10.3322/caac.21492
[7]	Ferlay J, Soerjomataram I, Dikshit R, et al. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-386. doi: 10.1002/ijc.29210
[8]	Minorics R, Bózsity N, Molnár J, et al. (2015) A molecular understanding of D-homoestrone-induced G2/M cell cycle arrest in HeLa human cervical carcinoma cells. J Cell Mol Med 19: 2365-2374. doi: 10.1111/jcmm.12587
[9]	Cho H, Chung JY, Song KH, et al. (2014) Apoptosis inhibitor-5 overexpression is associated with tumor progression and poor prognosis in patients with cervical cancer. BMC Cancer 14: 545. doi: 10.1186/1471-2407-14-545
[10]	Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26: 5802-5812.
[11]	Schoenborn JR, Wilson CB (2007) Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96: 41-101. doi: 10.1016/S0065-2776(07)96002-2
[12]	Li J, Fan C, Pei H, et al. (2013) Smart drug delivery nanocarriers with self-assembled DNA nanostructures. Adv Mater 25: 4386-4396. doi: 10.1002/adma.201300875
[13]	Dalpke A, Frank J, Peter M, et al. (2006) Activation of toll-like receptor 9 by DNA from different bacterial species. Infect Immun 74: 940-946. doi: 10.1128/IAI.74.2.940-946.2006
[14]	Krieg AM (2004) Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 6: 88-95. doi: 10.1007/s11912-004-0019-0
[15]	Kiziltas S (2016) Toll-like receptors in pathophysiology of liver diseases. World J Hepatol 8: 1354-1369. doi: 10.4254/wjh.v8.i32.1354
[16]	Tiwari RK, Singh S, Gupta CL, et al. (2020) Microglial TLR9: plausible novel target for therapeutic regime against glioblastoma multiforme. Cell Mol Neurobiol online ahead of print.
[17]	Tiwari RK, Gupta CL, Bajpai P (2020) Impelling TLR9: road to perspective vaccine for visceral leishmaniasis. Drug Dev Res online ahead of print.
[18]	Hari A, Flach TL, Shi Y, et al. (2010) Toll-like receptors: role in dermatological disease. Mediators Inflamm 2010: 437246. doi: 10.1155/2010/437246
[19]	Melisi D, Frizziero M, Tamburrino A, et al. (2014) Toll-Like receptor 9 agonists for cancer therapy. Biomedicines 2: 211-228. doi: 10.3390/biomedicines2030211
[20]	Thomas S, Quinn BA, Das SK, et al. (2013) Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets 17: 61-75. doi: 10.1517/14728222.2013.733001
[21]	Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35: 495-516. doi: 10.1080/01926230701320337
[22]	Zhang J, Liu J, Zhu C, et al. (2017) Prognostic role of vascular endothelial growth factor in cervical cancer: a meta-analysis. Oncotarget 8: 24797-24803. doi: 10.18632/oncotarget.15044
[23]	Tiwari RK, Singh S, Gupta CL, et al.Repolarization of glioblastoma macrophage cells using non-agonistic Dectin-1 ligand encapsulating TLR-9 agonist: plausible role in regenerative medicine against brain tumor. Int J Neurosci (2020) .1-8. doi: 10.1080/00207454.2020.1750393
[24]	Ansari IA, Ahmad A, Imran MA, et al. (2020) Organosulphur compounds ınduce apoptosis and cell cycle arrest in cervical cancer cells via downregulation of HPV E6 and E7 oncogenes. Anticancer Agents Med Chem online ahead of print.
[25]	Zucchini N, de Sousa G, Bailly-Maitre B, et al. (2005) Regulation of Bcl-2 and Bcl-xL anti-apoptotic protein expression by nuclear receptor PXR in primary cultures of human and rat hepatocytes. Biochim Biophys Acta 1745: 48-58. doi: 10.1016/j.bbamcr.2005.02.005
[26]	Gallo O, Franchi A, Magnelli L, et al. (2001) Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3: 53-61. doi: 10.1038/sj.neo.7900127
[27]	Yoshida S, Amano H, Hayashi I, et al. (2003) COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab Invest 83: 1385-1394. doi: 10.1097/01.LAB.0000090159.53224.B9
[28]	Abdul Rahman SF, Muniandy K, Soo YK, et al. (2020) Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines. Biochem Biophys Rep 22: 100756.
[29]	Urban-Wojciuk Z, Khan MM, Oyler BL, et al. (2019) The role of TLRs in anti-cancer ımmunity and tumor rejection. Front Immunol 10: 2388. doi: 10.3389/fimmu.2019.02388
[30]	Yu L, Wang L, Li M, et al. (2010) Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother 59: 1021-1028. doi: 10.1007/s00262-010-0825-1
[31]	Wardak S (2016) Human Papillomavirus (HPV) and cervical cancer. Med Dosw Mikrobiol 68: 73-84.
[32]	Bosch FX, de Sanjosé S (2007) The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 23: 213-227. doi: 10.1155/2007/914823
[33]	Cannella F, Pierangeli A, Scagnolari C, et al. (2015) TLR9 is expressed in human papillomavirus-positive cervical cells and is overexpressed in persistent infections. Immunobiology 220: 363-368. doi: 10.1016/j.imbio.2014.10.012
[34]	McCall KD, Muccioli M, Benencia F (2020) Toll-Like receptors signaling in the tumor microenvironment. Adv Exp Med Biol 1223: 81-97. doi: 10.1007/978-3-030-35582-1_5
[35]	Castellsagué X (2008) Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 110: S4-S7. doi: 10.1016/j.ygyno.2008.07.045
[36]	Leahy KM, Koki AT, Masferrer JL (2000) Role of cyclooxygenases in angiogenesis. Curr Med Chem 7: 1163-1170. doi: 10.2174/0929867003374336
[37]	Hoellen F, Waldmann A, Banz-Jansen C, et al. (2016) Expression of cyclooxygenase-2 in cervical cancer is associated with lymphovascular invasion. Oncol Lett 12: 2351-2356. doi: 10.3892/ol.2016.4925
[38]	Bora NS, Mazumder B, Mandal S, et al. (2019) Amelioration of UV radiation-induced photoaging by a combinational sunscreen formulation via aversion of oxidative collagen degradation and promotion of TGF-β-Smad-mediated collagen production. Eur J Pharm Sci 127: 261-275. doi: 10.1016/j.ejps.2018.11.004
[39]	Koh YW, Park C, Yoon DH, et al. (2013) Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma. Am J Surg Pathol 37: 1242-1251. doi: 10.1097/PAS.0b013e31828b6ad3
[40]	Song EL, Hou YP, Yu SP, et al. (2011) EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer in vivo. Gynecol Oncol 121: 174-180. doi: 10.1016/j.ygyno.2010.11.004

Reader Comments

Your name:*

Email:*
© 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)